Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | IDH2 | P48735 | 1/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.47 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.47 |
| ▸ | HTR6 | P50406 | 4/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3801837 | 1.00 | KDM1A (0.54) | KDM1AMAOBIDH2PRKCZPRKD2 | |
| SCHEMBL24699318 | 1.00 | KDM1A (0.54) | KDM1AMAOBIDH2PRKCZPRKD2 | |
| SCHEMBL17961734 | 0.89 | KDM1A (0.51) | KDM1AMAOBIDH2CHEK2HTR6 | |
| SCHEMBL2343007 | 0.89 | KDM1A (0.51) | KDM1AMAOBIDH2CHEK2HTR6 | |
| Hydrochloric Acid SCHEMBL14862165 | 0.87 | KDM1A (0.50) | KDM1AMAOBIDH2CHEK2HTR6 | |
| Hydrochloric Acid SCHEMBL32664670 | 0.87 | KDM1A (0.50) | KDM1AMAOBIDH2CHEK2HTR6 | |
| SCHEMBL4965283 | 0.85 | CHEK2 (0.47) | KDM1AMAOBCHEK2HTR6 | |
| SCHEMBL27178730 | 0.84 | PRKCZ (0.43) | KDM1AMAOBIDH2PRKCZHTR6 | |
| SCHEMBL24596919 | 0.82 | FPR2 (0.54) | KDM1AMAOBIDH2PRKCZHTR6 | |
| SCHEMBL661039 | 0.82 | PRKCZ (0.55) | IDH2PRKCZPRKD2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119569641-A | Synthesis method of nilaparib intermediate 4- (piperidin-3-yl) aniline | 山东铂源药业股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-119569641-A | Synthesis method of nilaparib intermediate 4- (piperidin-3-yl) aniline | 山东铂源药业股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119569641-A | Synthesis method of nilaparib intermediate 4- (piperidin-3-yl) aniline | 山东铂源药业股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119569641-A | Synthesis method of nilaparib intermediate 4- (piperidin-3-yl) aniline | 山东铂源药业股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| EP-2900666-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Ignyta, Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| CN-102675280-B | Trifluoromethyl-containing indole ketone compound,and preparation method and application thereof | SHANGHAI INST ORGANIC CHEM | 2015-01-14 | — | — | CN | disclosed |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-5292738-A | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-03-08 | — | — | US | disclosed |
| US-5157035-A | Viricides | JANSSEN PHARMACEUTICA N. V. (BE) | 1992-10-20 | — | — | US | disclosed |
| US-5001125-A | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-03-19 | — | — | US | disclosed |
| EP-0156433-B1 | ANTI-VIRALLY ACTIVE PYRIDAZINAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-27 | — | — | EP | disclosed |
| US-4798897-A | (AMINOALKYL)AMINOSULFONYL-SUBSTITUTED CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1989-01-17 | — | — | US | disclosed |
| EP-0156433-A2 | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | KDM1A 3702/4885MAOB 3552/4885IDH2 2541/4885 |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | KDM1A 1114/4885MAOB 4396/4885IDH2 3600/4885 |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | KDM1A 1175/4885MAOB 4418/4885IDH2 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.